Added value of serial bio-adrenomedullin measurement in addition to lactate for the prognosis of septic patients admitted to ICU
- PMID: 32111263
- PMCID: PMC7048063
- DOI: 10.1186/s13054-020-2794-x
Added value of serial bio-adrenomedullin measurement in addition to lactate for the prognosis of septic patients admitted to ICU
Conflict of interest statement
AM has received speaker’s honoraria from Novartis, Orion, and Servier and fees as a member of the advisory board and/or steering committee from Cardiorentis, Adrenomed, sphingotec, Sanofi, Roche, Abbott, and Bristol-Myers Squibb. EG has received consulting fees from Adrenomed, Roche Diagnostics, and Magnisense and lecture fees from Edwards Lifesciences. OH and JS are employees of sphingotec GmbH, the company that developed and holds patent rights in the bio-ADM assay. BC received fees as a member of an advisory board from Roche Diagnostics. The other authors declare that there are no competing interests.
Figures

Comment on
-
Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study.Crit Care. 2018 Dec 21;22(1):354. doi: 10.1186/s13054-018-2243-2. Crit Care. 2018. PMID: 30583748 Free PMC article.
References
-
- Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG, Blet A, et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care. 2018;22(1):354. doi: 10.1186/s13054-018-2243-2. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical